{
    "clinical_study": {
        "@rank": "67377", 
        "arm_group": {
            "arm_group_label": "Mapping and Biopsy", 
            "arm_group_type": "Experimental", 
            "description": "Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Diagnostic procedures, such as lymph node mapping and biopsy, may improve the\n      ability to detect the extent of colorectal cancer.\n\n      PURPOSE: Diagnostic trial to study the feasibility of lymph node mapping and sentinel lymph\n      node biopsy in patients who have stage I, stage II, or stage III colorectal cancer."
        }, 
        "brief_title": "Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer", 
        "completion_date": {
            "#text": "February 2002", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the feasibility of lymphatic mapping and sentinel lymph node biopsy\n      in patients with stage I, II, or III colorectal cancer. II. Evaluate technetium Tc 99m\n      sulfur colloid as a mapping agent in this patient population. III. Identify patients with\n      histologically negative nodes but have positive nodes on further detailed examination.\n\n      OUTLINE: Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur\n      colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes\n      following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the\n      sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary\n      tumor. Patients are followed postoperatively, every 4-6 months for 2 years, every 6 months\n      for 1 year, and then annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Preoperative diagnosis of stage I, II, or III colorectal cancer\n        No more than 90 days since diagnosis No tumor involving adjacent structures (T4 lesion) No\n        clinical or radiological evidence of stage IV disease No total excision of primary tumor\n        at diagnosis\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n        expectancy: Not specified Hematopoietic: Not specified Hepatic: No severe decompensated\n        liver disease, including cirrhosis Renal: Not specified Other: No known primary or\n        secondary immunodeficiencies No other medical conditions or evidence of infection that\n        would preclude study Not pregnant Negative pregnancy test\n\n        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior colonic, aortic, or\n        retroperitoneal surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005640", 
            "org_study_id": "MCC-11785", 
            "secondary_id": "NCI-G00-1780"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mapping and Biopsy", 
                "intervention_name": "Preoperative Endoscopy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Mapping and Biopsy", 
                "intervention_name": "Technetium Tc 99m Sulfur Colloid", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Mapping and Biopsy", 
                "intervention_name": "Gamma Probe", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Mapping and Biopsy", 
                "intervention_name": "Biopsy of Sentinel Lymph Nodes", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage I colon cancer", 
            "stage II colon cancer", 
            "stage III colon cancer", 
            "stage I rectal cancer", 
            "stage II rectal cancer", 
            "stage III rectal cancer"
        ], 
        "lastchanged_date": "September 24, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MCC-11785"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer: A Feasibility Study", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Timothy J. Yeatman, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Determine the feasibility of lymphatic mapping and sentinel lymph node biopsy in patients with stage I, II, or III colorectal cancer. Evaluate technetium Tc 99m sulfur colloid as a mapping agent in this patient population. Identify patients with histologically negative nodes but have positive nodes on further detailed examination.", 
            "measure": "Number of Procedures Resulting in Improved Detection", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005640"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1999", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "H. Lee Moffitt Cancer Center and Research Institute": "27.951 -82.457"
    }
}